Method, type of technology for testing a biomarker. Italicized choices represent various algorithms for reflexing to FISH test based on IHC results (0, 1+, 2+ and/or 3+). CISH = chromogenic in situ hybridization; FISH = fluorescence in situ hybridization; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; LBA = ligand-binding assay; PgR = progesterone receptor; RT-PCR = reverse transcription polymerase chain reaction; SISH = silver in situ hybridization. † Multimethod algorithm, a sequence of methods for testing one biomarker, when multiple methods are used. ‡ Reflex test, confirming equivocal or borderline results by another method. § Multibiomarker protocol, a sequence of testing multiple biomarkers.
Background
Molecular biomarkers, a cornerstone of precision oncology, are critical in breast, gastroesophageal, and nonsmall cell lung cancer management (BC, GEC, NSCLC). Testing practices are intensely debated, impacting diagnostic quality and affecting pathologists, oncologists and patients. However, little is known about testing approaches used in practice. Our study described biomarker practices in BC, GEC, and NSCLC at the leading US cancer centers.
Methods
We conducted a survey of the National Cancer Institute (NCI) designated centers on BC, GEC, and NSCLC biomarker testing. We used simple frequencies to describe practices, two-sided Fisher's exact test and two-sided McNemar's test for cross-cancer comparison. All statistical tests were two-sided.
Results
For BC human epidermal growth factor receptor 2 (HER2), 39% of centers combine guidelines by using in situ hybridization (ISH) and immunohistochemistry (IHC) concurrently, and 21% reflex-test beyond guideline-recommended IHC2+. For GEC HER2, 44% use ISH and IHC concurrently, and 28% reflex-test beyond IHC2+. In NSCLC, the use of IHC is limited to 4% for epidermal growth factor receptor (EGFR) and 7% for anaplastic lymphoma kinase (ALK). 43 .5% test NSCLC biomarkers on oncologist order; 34.5% run all biomarkers upfront, and 22% use a sequential protocol. NSCLC external testing is statistically significantly higher than BC (P < .0001) and GEC (P < .0001). NSCLC internally developed tests are statistically significantly more common than BC (P < .0001) and GEC (P < .0001).
Conclusions
At the NCI cancer centers, biomarker testing practices vary, but exceeding guidelines is a common practice for established biomarkers and emerging practice for newer biomarkers. Use of internally developed tests declines as biomarkers mature. Implementation of multibiomarker protocols is lagging. Our study represents a step toward developing a biomarker testing practice landscape. JNCI J Natl Cancer Inst (2014) 106(10): dju256 doi:10.1093/jnci/dju256
Molecular biomarkers play a transformative role in cancer management and facilitate emergence of precision oncology (1) (2) (3) (4) (5) (6) . Over 600 molecular tests are included in oncology guidelines (7) , and a host of new biomarkers will soon enter clinical practice (8, 9) . For many biomarkers, multiple testing methods and algorithms are available, each with limitations, causing quality variation and fueling ongoing debate on which testing practice is best (10) (11) (12) (13) . Guidelines include a range of alternative testing methods and algorithms, leaving room for institutional choice of practices (14) (15) (16) (17) (18) (19) (20) . The knowledge of realworld practices, among other factors, may inform institutional decisions and the overall debate on biomarker testing. However, this real-world knowledge is presently limited. We undertook this study to identify the practices National Cancer Institute (NCI)-designated cancer centers employ for biomarker testing in three common cancers. Our goal is to take a step toward developing a practice landscape for cancer biomarker testing, starting with NCI cancer centers-oncology thought leaders in the United States.
Biomarker testing practices affect accuracy and timeliness of results that guide decisions on potentially life-saving therapies (10, 13, 17, 20, 21) . Thus, these practices are of keen interest to not only pathologists, but also oncologists, surgeons, radiologists, and other disciplines involved in oncology care. Notably, experts call for multidisciplinary involvement in institutional decisions on biomarker testing (17, 20, (22) (23) (24) . Payers, patients, and the general public are also drawn into the discussion, as illustrated by testing for human epidermal growth factor receptor 2 (HER2) in breast cancer (25) (26) (27) (28) (29) (30) (31) .
Breast cancer (BC), gastric/esophageal cancers (GEC) and nonsmall cell lung carcinomas (NSCLC) are among cancers where biomarkers and targeted therapies have brought dramatic benefit: they transformed management of BC (32) (33) (34) , extended survival in advanced GEC (35) , and revolutionized management of NSCLC (Table 1) (36) (37) (38) (39) . Biomarker testing practices in these cancers are the subject of keen interest and extensive debate (13, (17) (18) (19) 22, (55) (56) (57) (58) (59) (60) (78) (79) (80) (81) , with a spectrum of available testing methods and approaches, as summarized in Table 1 . However, knowledge of practices employed at US cancer centers is limited to reports of institutional experiences (76, 96, 102, (104) (105) (106) (107) (108) and expert estimates (45) . Proficiency surveys, although highly important, rightfully focus on technical aspects rather than algorithm and protocol practices (109, 110) . Our study included clinically relevant biomarkers in BC, GEC, and NSCLC (Table 1) : HER2, estrogen receptor (ER), progesterone receptor (PgR) in BC, HER2 in GEC, and epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) in NSCLC.
Taken together, BC, GEC, and NSCLC represent an epitome of molecular profiling practices. The HER2 debate, notably immunohistochemistry vs fluorescence in situ hybridization (FISH), is relevant to other cancers where HER2 amplification becomes a therapeutic target (67) (68) (69) and is permeating other areas (ALK, EGFR) where immunohistochemistry is proposed to augment existing methods (70, 75, 76, 91, 92) . GEC exemplifies how testing practices transcend across cancers (81) , and NSCLC has become a paradigm for multibiomarker profiling (103) .
Introduction of new biomarkers is expected to accelerate (6, 8, 9, 96, 111) with potential application of targets across cancers (112) and adoption of next generation sequencing of tumor tissue (113) (114) (115) (116) (117) (118) . Understanding the current testing landscape may contribute lessons learned across cancers and inform integration of new biomarkers and technologies into practice. Our study is a step toward developing such a practice landscape.
Methods

Study Design and Survey Development
The study was approved by the institutional review board of Northwestern University. We developed a cross-sectional internet-based survey, with expert input from three pathologists and three oncologists in BC, GEC, and/or NSCLC. We piloted the survey individually with six pathologists and six oncologists in BC, GEC, and/or NSCLC and adjusted the instrument based on their feedback. The final survey instrument contained 12 BC, three GEC, and eight NSCLC questions about methods for testing individual biomarkers, multimethods algorithms for assessing one marker, multibiomarker testing protocols, whether testing was conducted internally or externally, and whether commercial tests or internally developed tests were used (Supplementary Methods, available online). The instrument contained multiple-choice questions, including "not used" and "I don't know" options as relevant. A comment area followed each question. An internet survey provider (www.surveymonkey. com, SurveyMonkey, Palo Alto, CA) was used to configure and administer the survey.
Survey Sample and Recruitment
The unit of analysis was cancer centers. We followed the American Association for Public Opinion Research (AAPOR) guidelines for establishment surveys to identify target respondents (119) . Of the 66 NCI-designated cancer centers listed on the NCI website (120), we identified 58 providing adult oncology care. We contacted directors of the 58 centers asking to identify target respondents-pathologists and oncologists in BC, GEC, and NSCLC. The majority of directors (75%) provided contact information. We identified target respondents for remaining centers from their websites. We included additional contacts when suggested by our target respondents.
Data were collected between July and November 2012. Individual emails were sent from the principal investigator describing the study and providing a link to the survey. A study investigator tracked responses to study identification numbers to determine which centers and/or targets had responded, and to link individual responses to the center level in an anonymous secure fashion. No other investigator had access to the identifiable information. Up to three follow-up emails were sent to nonrespondents, following the Dillman tailored design method for internet surveys (121) .
Statistical Analysis
Information collected was coded and rolled up to de-identified institutions following the AAPOR establishment survey methodology (119) . If only one participant responded from an institution, that response was used. If multiple responses were received per institution, two investigators independently coded the consented results to the institution identification number according to a predetermined hierarchy. The investigators compared their coding and had no conflicts at the institutional level. Coding was reviewed by the principal investigator. Coded results by de-identified institution were entered into statistical software (STATA 12, StataCorp, College Station, TX). Simple frequencies were used to describe practices, two-sided McNemar's test of matched proportions to compare BC and GEC HER2 testing practices, and two-sided Fisher's exact test to compare in-house testing and development practices between cancers. All statistical tests were two-sided.
results
We achieved an overall survey response rate of 98% (57/58 institutions), with response rates of 98% to BC, 93% to GEC, and 95% to NSCLC questions. We found no conflict in responses from participants within sites. Table 2 summarizes respondents' characteristics.
Breast Cancer Biomarker Testing
All BC respondents conduct HER2, ER, and PgR testing. For HER2 testing, 81% use IHC, all in an algorithm with ISH. All sites use ISH, alone or in an algorithm with IHC: 91% use fluorescence in situ hybridization (FISH), 5% use silver in situ hybridization (SISH), 4% use chromogenic in situ hybridization (CISH), and 2% (one site) use FISH and CISH (Table 3) . Among the seven distinct algorithms reported for HER2 testing, "IHC, reflex to FISH" is most common (42%), followed by concurrent FISH and IHC testing (30%), and by "FISH alone" (18% 
Gastric/Esophageal Cancer Biomarker Testing
All GEC respondents conduct HER2 testing (Table 4 ). IHC is used by 83% of respondents, all in an algorithm with ISH. All respondents use an ISH method, most commonly FISH (94%). Concurrent FISH and IHC testing is most common (41%), followed by "IHC, reflex to FISH" (39%), "FISH alone" (13%), and concurrent "IHC and SISH or CISH" (4%). Overall, 44% of centers use IHC and a type of ISH (FISH, SISH or CISH) concurrently. Among the 21 sites using "IHC, reflex to FISH" algorithm, all reflex-test IHC2+ results, as recommended in guidelines, and 71% (15/21) of these sites, or 28% (15/54) of all responding sites, reflex-test at least one other IHC result. Among the 15 sites conducting expanded reflex testing, 53% (8/15) do so as a standard protocol and 47% (7/15) on oncologist order.
Non-Small Cell Lung Cancer Biomarker Testing
All NSCLC section respondents conduct EGFR and ALK testing, and 96% test KRAS ( 
Practice Comparison Across Cancers
Comparing the use of BC and GEC HER2 testing practices among 54 respondents to both sections, we determined that 61% Retest HER2 for triple-positive cancers 1 (2) of institutions use a similar algorithm. Among sites using different GEC vs BC algorithms, 20% use "concurrent IHC and ISH" in GEC, 15% use IHC, reflex to ISH in GEC, and 4% use ISH in GEC, but not BC. The two-sided McNemar's test of matched proportions (statistical significance cutoff P = .05) showed lack of statistically significant association between the BC and GEC HER2 practices within these institutions: 39% use "concurrent IHC and ISH" for BC, while 46% use this algorithm for GEC (P = .35); 43% use "IHC, reflex to ISH" for BC, while 39% use this algorithm for GEC (P = .64); and 19% use "ISH alone" for BC, while 15% use this algorithm for GEC (P = .41). BC and GEC HER2 and ER/PgR testing are performed predominantly in-house (Table 6) , with a similar rate of internal testing between BC and GEC (93% vs 92%, P = .8232), while the rate of external NSCLC testing, at 36%, is statistically significantly higher than BC at 7% (P < .0001) and GEC at 8% (P < .0001). In-house testing is performed with internally developed tests more commonly in NSCLC than in BC or GEC (80% vs 10%, P < .0001, and 80% vs 21%, P < .0001, respectively), and more commonly in GEC than in BC (21% vs 10%, P = .0175). The choice of methods, algorithms or protocols in BC, GEC, and NSCLC had no association with institution size, metro vs nonmetro location, or whether the institution held NCCN designation. The two-sided Fisher's exact test was used here (statistical significance cutoff P = .05).
Discussion
We surveyed the NCI-designated cancer centers on their biomarker testing practices in three common cancers: breast, gastroesophageal, and non-small cell lung. While testing practices vary across NCI centers, findings indicate several similarities. These include testing beyond guidelines as a common practice for established biomarkers and an emerging practice for new biomarkers. Using internally developed tests is lower for mature than for emerging biomarkers. Implementation of institutional multibiomarker protocols lags guidelines.
We found variability of testing practices across the NCI centers: we identified seven distinct HER2 testing algorithms in BC and GEC, three or more testing methods for each NSCLC biomarker, and six NSCLC multibiomarker protocols. Variability is hardly surprising, given that respective guidelines allow multiple testing approaches (14) (15) (16) (17) (18) (19) (20) and published studies advocate the merit of additional approaches beyond guidelines (51) (52) (53) (54) 79, 80, 82, 83) . Establishing an experience-based minimally acceptable standard for biomarker testing may be desirable to support institutional decision-making between guideline-and literature-recommended choices. However, practice variability, even at the leading centers, is a barrier to establishing such standards. The evolving nature of the biomarker field and emergence of new testing methods and protocols could make standardization a moving target. Further research should elucidate drivers and consequences of various testing practices, including patient outcomes, cost, and cost-effectiveness, to inform institutional decision-making and pave the way to establishing a standard.
Despite variability, we found several common practices across NCI centers. First, we identified that testing beyond guidelines has become a common practice for HER2 assessment in BC and GEC. ASCO/CAP HER2 BC guidelines offer institutional choice of "IHC, reflex IHC2+ to ISH," or ISH-testing algorithms (20) . Previous US estimates indicated 80% use of the former and 20% of the latter (123) . However, we found that only 42% of NCI sites use "IHC, reflex IHC to ISH," and half of those expand confirmatory testing beyond IHC2+. We also found that 39% of NCI centers use concurrent testing of IHC and ISH upfront. Concurrent testing was previously documented by a utilization study (21%) (124), but we found it a more frequent practice at the NCI centers. Eleven percent of NCI centers also retest triple-positive and/or triplenegative cases. Respondents' comments specify quality assurance and literature as reasons for the above practices. We found similarity in overall frequencies of concurrent and expanded reflex-test algorithms between GEC and BC, as well as similarity of BC and GEC algorithms within the majority of the centers. However, the association between BC and GEC practices was not statistically significant; and a sizable minority of centers employed different approaches in these two cancers. Respondent comments indicate quality assurance, literature, and the emerging nature of GEC HER2 testing as reasons for concurrent and expanded reflex-test practices. Together, these findings suggest that both intrainstitutional and the overall field experience in BC HER2 testing inform GEC HER2 testing practices.
Respondents' comments indicate that exceeding guidelines is their strategy to assure testing quality in the HER2 field where intense debate over testing approaches persists, even within the ASCO/CAP guideline panel (125) . Each guideline-recommended approach still has shortcomings, potentially leading to misdiagnosis of some patients (10, 11, 44, 55, 79, 85, 123) . Studies show that practices of combining approaches and exceeding guidelines mitigate some shortcomings and allow incremental improvement of testing accuracy (51) (52) (53) (54) 77, (80) (81) (82) (83) . However, such improvement comes at a cost. While the literature shows that some HER2 practices beyond guidelines are cost-effective (eg, reflex-testing IHC0 and IHC1+ results) (51), other practices, such as concurrent IHC/ISH or retesting triple-negative or triple-positive cases, have not been assessed for cost-effectiveness. We didn't examine whether the NCI centers analyzed or considered cost-effectiveness of their testing practices. These and other academic centers are typically well resourced, with access to donor funding, affording extra efforts to improve quality. They also conduct research, which may contribute to feasibility of their practices: trials may require certain HER2 protocols (eg, retesting all IHC cases with FISH), potentially impacting overall institutional testing practices. Community-based centers without such protocols and donor funding may not have resources or experience for extra efforts. The costs of incremental quality improvement may be prohibitive to these centers, even if the improvements prove cost-effective. To determine applicability of NCI center practices to other settings, cost-effectiveness and net institutional budget impact of testing practices, along with patient outcomes, should be assessed.
The second common dynamic we identified is the emergence of going beyond guidelines in NSCLC. A debate on best methods, analogous to HER2 testing, is now emerging in NSCLC (70) . For example, IHC is proposed as a less costly "screening" tool for EGFR (75) and ALK (76, (91) (92) (93) testing, followed by molecular analysis in positive cases, and guidelines, in the case of ALK, allow this approach, when carefully validated (18) . Our study showed that only a small minority of NCI centers use IHC for EGFR and/or ALK testing, indicating that they exercise the recommended caution (18, 92) toward this approach, despite the cost advantage. The trajectory of the HER2 debate toward exceeding guidelines to avoid any misdiagnosing (51, 123) may be emerging in NSCLC. Similarly, patient outcome, cost-effectiveness, and budget-impact implications of these practices should be assessed in NSCLC.
We found that NCI centers have universally adopted new biomarkers (GEC HER2; NSCLC ALK, EGFR mutation), but are still developing NSCLC multimarker testing protocols: nearly half of respondents run these tests based on oncologist order. Guidelines recommend either a concurrent or sequential protocol, with result turnaround time within 10 business days (18) . However, we found that among NCI centers with an established NSCLC protocol, the majority assess all biomarkers upfront-a practice associated with shorter result turnaround time and better sample management, but with higher costs. Although still evolving, these practices may also signify a trend, similar to that in HER2 testing, toward higher quality despite higher costs and should be assessed for patient outcome, cost-effectiveness, and budget-impact implications.
The third common dynamic identified across NCI centers is the lower use of internally developed tests for mature vs novel biomarkers. This is yet another controversial area (10, 126, 127) , especially given the US Food and Drug Administration's (FDA's) recent intention to tighten regulation of cancer biomarker tests (128) . Our findings indicate a trend from higher external and/or internally developed testing for new biomarkers (NSCLC) to predominant use of commercial kits for mature markers (BC). This indicates that NCI centers adopt commercially available kits "voluntarily" over time, even in the absence of regulation. For example, testing for ALK, the newest biomarker in our study, with a commercial test is higher than for other NSCLC tests, perhaps because an FDAapproved test is available.
Our study had a number of limitations. Our findings were selfreported by participants, a common limitation of surveys, but mitigated by the fact that we did not receive conflicting input within responding sites. While we collected data on reasons for several specific testing practices, future studies should more comprehensively elucidate factors and motivations influencing testing practices. Practices at NCI centers may be representative of other large academic centers, but may not be indicative of practices in the community setting where donor funding and research experiences are more limited. Further studies should examine biomarker testing practices at community cancer centers, to fully understand the landscape of practices in the US. To guide applicability of our findings, and future studies, to other settings in the environment of rising healthcare costs and unaffordability concerns, the testing practice landscape should be coupled with assessment of cost-effectiveness, budget impact, and patient outcomes.
In conclusion, our survey of NCI-designated cancer centersthe leading US oncology institutions-showed that while testing approaches vary, exceeding guidelines to ensure testing quality is a common practice for established biomarkers, and an emerging practice for new biomarkers. Implementation of multimarker testing protocols is lagging and should be addressed at the NCI centers and other institutions. Our study is a step toward developing a landscape of cancer biomarker testing practices in the US. Future inclusion of community practices, expansion to other biomarkers and cancers, and studies of outcomes and cost-effectiveness of testing practices will be necessary to evolve the landscape. 
